Page 188 - EJMO-9-3

Eurasian Journal of
Medicine and Oncology Research on DSY in treating gastritis

Table 5. Degree, betweenness, and closeness values of potential bioactive compounds in DSY targeting gastritis
Serial number Compound name Degree Betweenness Closeness Sources
LCDSY-3 Citric acid 92 33661.1680 0.1223 DSY, DS
LCDSY-31 Rosmarinic acid 28 7463.3510 0.1155 DSY, DS
LCDSY-45 Tanshinone IIA 25 6402.2240 0.1144 DSY, DS
LCDSY-14 Caffeic acid 24 6760.6210 0.1158 DSY, DS
LCDSY-11 Epicatechin 24 5167.0913 0.1149 DSY, SR
LCDSY-46 Cryptotanshinone 16 2765.5713 0.1143 DSY, DS
LCDSY-29 Salvianolic acid B 16 5837.8240 0.1124 DSY, DS
LCDSY-6 Danshensu 13 2847.7444 0.1134 DSY, DS
LCDSY-15 Catechin 12 1437.6676 0.1137 DSY, SR
LCDSY-43 Isocryptotanshinone 11 1593.7957 0.1137 DSY, DS
LCDSY-42 Neocryptotanshinone 10 803.9311 0.1137 DSY, DS
LCDSY-9 Protocatechuic acid 9 1740.7864 0.1136 DSY, DS, SR
LCDSY-7 Vanillin 8 1034.0078 0.1136 DSY, TX
LCDSY-20 Salvianolic acid A 7 509.3273 0.1121 DSY, DS
LCDSY-10 3,4-Dihydroxyhydrocinnamic acid 7 717.6403 0.1128 DSY, DS
LCDSY-8 Vanillic acid 7 737.9602 0.1135 DSY, SR
LCDSY-12 Protocatechualdehyde 6 1142.4958 0.1123 DSY, DS, SR
GCDSY-8 Isovanillin 5 471.3908 0.1132 DSY, DS
GCDSY-7 Bornyl acetate 4 600.2523 0.1105 DSY, SR, TX
GCDSY-15 Diepicedrene-1-oxide 3 515.2957 0.1034 DSY, TX
GCDSY-3 Benzeneacetaldehyde 3 461.9877 0.1066 DSY, SR, DS
GCDSY-13 Cryptomeridiol 2 15.5880 0.1101 DSY, DS
Notes: Degree refers to the number of connections to other nodes in the network. Betweenness refers to the frequency of a node appearing on shortest
paths between nodes. Closeness refers to the average shortest path from the node to all other nodes.
Abbreviations: DS: Salvia miltiorrhiza Bge.; DSY: Dan-Shen-Yin; SR: Amomum villosum Lour.; TX: Santalum album L.

binding transcription factor binding, cytokine activity, and treatment of gastritis. The analysis identified 22 bioactive
protein kinase activity were enriched. compounds, potentially representing the key material
As shown in Figure 8F, the KEGG enrichment basis by which DSY exerts its therapeutic effects. At
analysis indicated that 10 out of the top 20 pathways present, most of these compounds have been previously
(total = 170 pathways) were associated with inflammation. reported in pharmacological studies to exhibit a range of
These include lipid and atherosclerosis, fluid shear stress activities relevant to the treatment of gastritis. For instance,
and atherosclerosis, MAPK signaling pathway, JAK-STAT rosmarinic acid has a significant gastric protective effect
31
signaling pathway, inflammatory bowel disease, nuclear as it increases antioxidant defense and PGE secretion.
2
32
factor-kappa B (NF-κB) signaling pathway, p53 signaling Hiruma Lima et al. found that Epi present in Virola
surinamensis resin exhibits anti-ulcer activity. Catechin
pathway, rheumatoid arthritis, leukocyte transendothelial and isocryptotanshinone have the potential preventive
migration, and cell cycle. A disease-core target-compound- effects against gastric carcinogenesis. 33,34 Cheng et al.
35
pathway network constructed using Cytoscape 3.9.1 proposed that protocatechuic acid can treat oxidative
exhibited 134 nodes and 346 edges (Figure 8F). This stress-associated gastrointestinal ulcer diseases by inducing
network illustrates that one compound can act on multiple Parkinson disease protein 7 (DJ-1) expression. The results
targets while multiple compounds act on a common target, of Murakami et al. indicated that salvianolic acid A
36
and the targets are involved in different signaling pathways.
shows antisecretory and anti-ulcer activity by inhibiting
In summary, this study employed network pharmacology the gastric H , K -ATPase. Ren et al., using a rat model
37
+
+
analysis based on the comprehensive characterization of of chronic atrophic gastritis (CAG), demonstrated that
DSY decoction, thereby elucidating its active compounds, tanshinone IIA may alleviate inflammation and cellular
core targets, and associated pathways involved in the apoptosis by inhibiting the activation of the JAK2/
Volume 9 Issue 3 (2025) 180 doi: 10.36922/EJMO025160124